HUGE FSD Pharma Earnings per share increase in current year

FSD Pharma Inc. (HUGE) develops innovative drugs to combat depression and neurodegenerative pathologies. The annual EPS change scale visualizes current yield dynamics, with the 0.00 mark reflecting the latest data. The company is optimizing costs by outsourcing formula synthesis and clinical trials to external contractors. Management is currently restructuring R&D processes, aiming for strict resource austerity to regain shareholder confidence.

Earnings per share growth in current year: fsdpharma.com (HUGE) for 07/04/2022 - 08/15/2024

Financial and market metric breakdowns for FSD Pharma Inc. (HUGE)

- market value and analyst target forecast:

Stock Price FSD Pharma, Inc.|HUGE - Price Target Chart

- market capitalization data:

Market Value FSD Pharma Inc.|HUGE - Total Company Value

- business book valuation details:

Net Asset Value per Share FSD Pharma|HUGE - Company Book Value|Market Value to Book Value Ratio fsdpharma.com|HUGE - Aggregate Company Assets

- debt and liquidity details:

- company profitability and valuation multiples indicators:

HUGE - Net Profit|Net Profit Forecast FSD Pharma Inc.|HUGE - Price to Earnings Ratio|Future Price to Earnings Multiple FSD Pharma, Inc.|HUGE - Price/Earnings to Growth Ratio|Company Value to Operating Income Before Depreciation Ratio FSD Pharma Inc.|HUGE - Operating profit EBITDA|Earnings per share for the trailing year FSD Pharma|HUGE - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth fsdpharma.com|HUGE - Earnings per share growth in current year|Expected earnings per share trend next year FSD Pharma Inc.

- revenue and sales proceeds data:

HUGE - Company Revenue|Company Future Sales Volume fsdpharma.com|HUGE - P/S Multiple|Forward P/S Multiple FSD Pharma Inc.

Summary company analysis:HUGE FSD Pharma, Inc.

The eps_yy_co metric measures the annual percentage change in earnings per share, reflecting the growth rate of the business's real returns. This metric allows investors to assess capital management efficiency and the pace of profit scaling. When analyzing EPS YoY dynamics, one must consider the specific nature of FSD Pharma Inc. (HUGE), where financial results depend directly on the binary outcomes of clinical trials and FDA approvals.

Direct competitors